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To identify molecular targets in leukemia stem cells (LSCs), this study compared the protein expression profile of 
freshly isolated CD34+/CD38- cells with that of CD34+/CD38+ counterparts from individuals with acute 
myelogenous leukemia (n=2, AML) using isobaric tags for relative and absolute quantitation (iTRAQ). A total of 
98 proteins were overexpressed, while six proteins were underexpressed in CD34+/CD38- AML cells compared 
with their CD34+/CD38+ counterparts. Proteins overexpressed in CD34+/CD38- AML cells included a number of 
proteins involved in DNA repair, cell cycle arrest, gland differentiation, anti-apoptosis, adhesion, and drug 
resistance. Aberrant expression of CD82, a family of adhesion molecules, in CD34+/CD38- AML cells was noted 
in additional clinical samples (n=12) by flow cytometry. Importantly, down-regulation of CD82 in CD34+/CD38-
AML cells by a short hairpin RNA (shRNA) stimulated their migration via up-regulation of matrix 
metalloproteinases 9 (MMP9), as assessed by transwell assay and real time RT-PCR, respectively. Moreover, we 
found that down-regulation of CD82 in CD34+/CD38- AML cells by an shRNA significantly impaired 
engraftment of these cells in severely immunocompromised mice. Taken together, aberrant expression of CD82 
might play a role in adhesion of LSCs to bone marrow microenvironment. CD82 could be an attractive molecule 
target to eradicate LSCs. 
